Restore Medical has announced preliminary results of the first-in-human clinical trial of ContraBand, a breakthrough treatment for patients suffering from congestive heart failure. The minimally-invasive, catheter-delivered implants are used to treat patients with chronic left ventricular failure.
ContraBand has been implanted in its first patients at the ZNA Medical Center, Antwerp, Belgium, followed by Kaplan Medical Center, Rehovot, Israel.
“These first procedures are milestones in proving the ContraBand technology to be both safe and effective for heart failure patients,” said Gilad Marom, CEO of Restore Medical. “The positive impact this treatment can have on the millions of people suffering from congestive heart failure cannot be underestimated. Not only will it transform the quality of life of treated patients, but it will also reduce the enormous financial burden that comes as a result of patients being undertreated.”
The ContraBand is expected to relieve symptoms and improve patients’ quality of life by causing the healthy right ventricle to assist the failing left ventricle.
Source CardiovascularNews
Duc Tin Clinic
Tin tức liên quan
Performance diagnostique de l’interféron gamma dans l’identification de l’origine tuberculeuse des pleurésies exsudatives
A Mixed Phenotype of Airway Wall Thickening and Emphysema Is Associated with Dyspnea and Hospitalization for Chronic Obstructive Pulmonary Disease.
Radiological Approach to Asthma and COPD-The Role of Computed Tomography.
Significant annual cost savings found with UrgoStart in UK and Germany
Thrombolex announces 510(k) clearance of Bashir catheter systems for thromboembolic disorders
Phone: (028) 3981 2678
Mobile: 0903 839 878 - 0909 384 389